AbbVie’s Skyrizi nabs psoriatic arthritis nod, its second, shortly after Rinvoqnews2022-01-24T14:03:01+00:00January 24th, 2022|Fierce Pharma|
AbbVie’s Skyrizi nabs psoriatic arthritis nod, its 2nd, shortly after Rinvoqnews2022-01-24T14:03:01+00:00January 24th, 2022|Fierce Pharma|
AstraZeneca taps E! host Nina Parker for asthma campaign as it hopes new drug Tezspire can ‘break the cycle’news2022-01-24T13:59:34+00:00January 24th, 2022|Fierce Pharma|
Gilead’s Veklury expands FDA nod to patients outside the hospital as oral version heads to trialnews2022-01-24T11:57:12+00:00January 24th, 2022|Fierce Pharma|
BDSI readies liquid migraine medicine launch but stays away from ‘broad blast’ marketing campaignnews2022-01-24T09:29:59+00:00January 24th, 2022|Fierce Pharma|
Less selling, more science can best help doctors navigate complex new cancer treatments, report suggestsnews2022-01-23T18:51:05+00:00January 23rd, 2022|Fierce Pharma|
Poland’s largest pharma scouts for joint bidder in potential $4B buyout of former Sanofi generics unit: Reutersnews2022-01-21T16:30:35+00:00January 21st, 2022|Fierce Pharma|
Fierce JPM Week: Bristol Myers’ next-gen autoimmune med not just another JAK drug, exec saysnews2022-01-21T16:04:19+00:00January 21st, 2022|Fierce Pharma|
It’s a matter of national security: Sanofi doesn’t want new high-rise neighbors watching its Toronto plantnews2022-01-21T15:25:24+00:00January 21st, 2022|Fierce Pharma|
GlaxoSmithKline rushes to accelerate COVID-19 antibody output amid omicron-driven demandnews2022-01-21T14:50:58+00:00January 21st, 2022|Fierce Pharma|
